|
|
Volumn 33, Issue 4 Suppl, 2014, Pages
|
|
Therapeutic development in psoriasis.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
APREMILAST;
BRODALUMAB;
DRUG DERIVATIVE;
IMMUNOLOGIC FACTOR;
INTERLEUKIN 23;
IXEKIZUMAB;
MONOCLONAL ANTIBODY;
PHOSPHODIESTERASE INHIBITOR;
PIPERIDINE DERIVATIVE;
PROTEIN KINASE INHIBITOR;
PYRIMIDINE DERIVATIVE;
PYRROLE DERIVATIVE;
SECUKINUMAB;
THALIDOMIDE;
TOFACITINIB;
TUMOR NECROSIS FACTOR;
CLINICAL TRIAL (TOPIC);
DRUG ANTAGONISM;
HUMAN;
INFLAMMATION;
INTERLEUKIN-12/23;
JAK INTERLUKIN-17 INHIBITORS;
JANUS KINASE INHIBITORS;
PATHOPHYSIOLOGY;
PHOSPHODIESTERASE-4;
PSORIASIS;
REVIEW;
TREATMENT OUTCOME;
APREMILAST;
BRODALUMAB;
INFLAMMATION;
INTERLEUKIN-12/23;
IXEKIZUMAB;
JAK INTERLUKIN-17 INHIBITORS;
JANUS KINASE INHIBITORS;
MONOCLONAL ANTIBODY;
PHOSPHODIESTERASE-4;
PSORIASIS;
SECUKINUMAB;
TOFACITINIB;
TUMOR NECROSIS FACTORS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CLINICAL TRIALS AS TOPIC;
HUMANS;
IMMUNOLOGIC FACTORS;
INTERLEUKIN-23;
PHOSPHODIESTERASE INHIBITORS;
PIPERIDINES;
PROTEIN KINASE INHIBITORS;
PSORIASIS;
PYRIMIDINES;
PYRROLES;
THALIDOMIDE;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 84908555072
PISSN: 10855629
EISSN: None
Source Type: Journal
DOI: 10.12788/j.sder.0098 Document Type: Review |
|
Times cited : (9)
|
|
References (0)
|
